Results 291 to 300 of about 432,090 (383)

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Cabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration‐resistant prostate cancer (CRPC), yet it is typically reserved for post‐docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.
Taketo Kawai, Kazuki Maki, Satoru Taguchi, Yoichi Fujii, Takehiro Tanaka, Jimpei Miyakawa, Jun Kamei, Shigenori Kakutani, Aya Niimi, Daisuke Yamada, Yuta Yamada, Tappei Takada, Tohru Nakagawa, Haruki Kume   +13 more
wiley   +1 more source

Hereditary thrombocytopenias: the challenge of increasing frequency and differential diagnosis. [PDF]

Hematol Transfus Cell Ther
Çiftçiler R.
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Case Report: Severe thrombocytopenia in the context of concomitant tirofiban and ibuprofen use: does ibuprofen matter? [PDF]

Front Cardiovasc Med
Zhu J, Chen C, Zhu C, Sun L.
europepmc   +1 more source

Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Talazoparib is a poly(ADP‐ribose) polymerase inhibitor approved for the treatment of breast and prostate cancer. Commercialization of a soft gelatin capsule (SGC) formulation developed post‐approval required a bioequivalence (BE) and food effect (FE) study to bridge SGC with the initial commercial hard capsule (HC) formulation. Study execution
Diane Wang, Cathy Cen Guo, Xizhe Gao, Yibo Wang, Yanke Yu, Anna Plotka, Mohamed Elmeliegy, Haihong Shi, Samantha Johnson, Liza DeAnnuntis, Justin Hoffman   +10 more
wiley   +1 more source

Prevalence and factors associated with severe thrombocytopenia among hospitalized patients with malaria attending Kigeme District Hospital, Southern Province, Rwanda: cross-sectional study. [PDF]

Malar J
Ndatumuremyi J, Kagimbangabo JMV, Nshimiyimana I, Gaspard B, Sendegeya JP, Nizeyimana V, Byukusenge C, Nsanzabera C.   +7 more
europepmc   +1 more source

Recurrent endometrial carcinoma with immune-mediated thrombocytopenia following durvalumab: A case report. [PDF]

Case Rep Womens Health
Sakakibara A, Nagai S, Shirane T, Sakai T, Fujioka Y, Hino M, Hattori Y, Kurahashi T.   +7 more
europepmc   +1 more source

Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma. [PDF]

Cancer Med
Li X, Lai X, Wang X, Liu Q, Liu X, Wang L, Peng J, Chen P, Zhou H.   +8 more
europepmc   +1 more source

AUTOANTIBODIES AND AUTOREACTIVE B CELLS IN THE BONE MARROW AND THE PERIPHERAL BLOOD OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA

, 2019
Sabrina Shrestha
openalex   +1 more source

Dynamic biomarkers and Cox regression with time-dependent covariate for mortality prediction in severe fever with thrombocytopenia syndrome [PDF]

Hyun Woo, Sang Taek Heo, Jeong Rae Yoo, Mi-Sun Kim, Jaeseong Oh, In‐Gyu Bae, Sohyun Bae, Young‐Ran Yoon, Jeong‐Hwan Hwang, Miri Hyun, Hyun Ah Kim, Sook‐In Jung, Ki Tae Kwon, Soyoon Hwang, Uh Jin Kim, Gaeun Kang, Young Jun Kim, Ji Hyun Yun, Taeeun Kim, Tae‐Kyu Kwon, Min‐Gul Kim   +20 more
openalex   +1 more source